Page last updated: 2024-10-24

buspirone and Idiopathic Parkinson Disease

buspirone has been researched along with Idiopathic Parkinson Disease in 17 studies

Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.
buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.

Research Excerpts

ExcerptRelevanceReference
"Individuals with PD and clinically significant anxiety were randomized 4:1 to flexible dosage buspirone or placebo for 12 weeks."9.34A trial of buspirone for anxiety in Parkinson's disease: Safety and tolerability. ( Auinger, P; Gil-Díaz, MC; Iourinets, J; Richard, IH; Schneider, RB; Tarolli, CG, 2020)
"Individuals with PD and clinically significant anxiety were randomized 4:1 to flexible dosage buspirone or placebo for 12 weeks."5.34A trial of buspirone for anxiety in Parkinson's disease: Safety and tolerability. ( Auinger, P; Gil-Díaz, MC; Iourinets, J; Richard, IH; Schneider, RB; Tarolli, CG, 2020)
"Buspirone is a novel anxiolytic whose pharmacological profile differs from that of the benzodiazepines and includes dopaminergic agonist effects."2.66Buspirone, Parkinson's disease, and the locus ceruleus. ( Bakker, K; Bruno, G; Chase, TN; Gillespie, M; LeWitt, PA; Ludwig, CL; Weinberger, DR, 1986)
"Buspirone is a novel anxiolytic chemically unrelated to the benzodiazepines."2.66Buspirone in the treatment of tardive dyskinesia. ( Ross, CA, 1987)
"Buspirone treatment also improved mitochondrial function and antioxidant activities."1.72The Anxiolytic Drug Buspirone Prevents Rotenone-Induced Toxicity in a Mouse Model of Parkinson's Disease. ( Castorina, A; Thomas Broome, S, 2022)
" In this study we investigated the effect of chronic administration of buspirone and fluoxetine on cerebrospinal fluid (CSF) levels of inflammatory cytokines, TNF-α, IL-1β and IL-6 in 6-hydroxydopamine (6-OHDA)-lesioned rats."1.42Effect of Chronic Administration of Buspirone and Fluoxetine on Inflammatory Cytokines in 6-Hydroxydopamine-lesioned Rats. ( Farajnia, S; Haddadi, R; Nayebi, AM; Sharifi, H, 2015)
"The results suggest that compounds that indirectly facilitate 5-HT1 A receptor activation, such as citalopram, may be more effective therapeutics than direct 5-HT1 A receptor agonists because they exhibit similar anti-dyskinesia efficacy, while possessing a reduced side effect profile."1.42Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats. ( Bishop, C; Conti, MM; Lindenbach, D; Ostock, CY; Palumbo, N; Vilceus, N, 2015)
"The treatment of Parkinson's disease with grafts of fetal ventral mesencephalic tissue has shown some success, but can result in graft-induced dyskinesias (GIDs)."1.36Graft-induced dyskinesias in Parkinson's disease: what is it all about? ( Barker, RA; Kuan, WL, 2010)

Research

Studies (17)

TimeframeStudies, this research(%)All Research%
pre-19903 (17.65)18.7374
1990's2 (11.76)18.2507
2000's1 (5.88)29.6817
2010's8 (47.06)24.3611
2020's3 (17.65)2.80

Authors

AuthorsStudies
Thomas Broome, S1
Castorina, A1
Thomsen, M1
Stoica, A1
Christensen, KV1
Fryland, T1
Mikkelsen, JD1
Hansen, JB1
Schneider, RB1
Auinger, P1
Tarolli, CG1
Iourinets, J1
Gil-Díaz, MC1
Richard, IH1
Miyazaki, I1
Asanuma, M1
Murakami, S1
Takeshima, M1
Torigoe, N1
Kitamura, Y1
Miyoshi, K1
Politis, M1
Wu, K1
Loane, C1
Brooks, DJ1
Kiferle, L1
Turkheimer, FE1
Bain, P1
Molloy, S1
Piccini, P1
Sharifi, H1
Nayebi, AM1
Farajnia, S1
Haddadi, R1
Lindenbach, D1
Palumbo, N1
Ostock, CY1
Vilceus, N1
Conti, MM1
Bishop, C1
Beaulieu-Boire, I1
Fasano, A1
Levin, OS1
Paquette, MA1
Foley, K1
Brudney, EG1
Meshul, CK1
Johnson, SW1
Berger, SP1
Barker, RA1
Kuan, WL1
Shin, E1
Garcia, J1
Winkler, C1
Björklund, A1
Carta, M1
Bonifati, V1
Fabrizio, E1
Cipriani, R1
Vanacore, N1
Meco, G1
Kleedorfer, B1
Lees, AJ1
Stern, GM1
Ludwig, CL1
Weinberger, DR1
Bruno, G1
Gillespie, M1
Bakker, K1
LeWitt, PA1
Chase, TN1
Ross, CA1
Hammerstad, JP1
Carter, J1
Nutt, JG1
Casten, GC1
Shrotriya, RC1
Alms, DR1
Temple, D1

Trials

5 trials available for buspirone and Idiopathic Parkinson Disease

ArticleYear
A trial of buspirone for anxiety in Parkinson's disease: Safety and tolerability.
    Parkinsonism & related disorders, 2020, Volume: 81

    Topics: Aged; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Buspirone; Drug Tapering; Female; Humans;

2020
Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients.
    The Journal of clinical investigation, 2014, Volume: 124, Issue:3

    Topics: Aged; Antiparkinson Agents; Buspirone; Case-Control Studies; Dopamine; Double-Blind Method; Dyskines

2014
Buspirone in levodopa-induced dyskinesias.
    Clinical neuropharmacology, 1994, Volume: 17, Issue:1

    Topics: Aged; Buspirone; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Midd

1994
Buspirone, Parkinson's disease, and the locus ceruleus.
    Clinical neuropharmacology, 1986, Volume: 9, Issue:4

    Topics: Anti-Anxiety Agents; Buspirone; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-B

1986
Buspirone in the treatment of tardive dyskinesia.
    Medical hypotheses, 1987, Volume: 22, Issue:3

    Topics: Anti-Anxiety Agents; Buspirone; Clinical Trials as Topic; Dopamine; Dyskinesia, Drug-Induced; Humans

1987

Other Studies

12 other studies available for buspirone and Idiopathic Parkinson Disease

ArticleYear
The Anxiolytic Drug Buspirone Prevents Rotenone-Induced Toxicity in a Mouse Model of Parkinson's Disease.
    International journal of molecular sciences, 2022, Feb-06, Volume: 23, Issue:3

    Topics: Animals; Buspirone; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regula

2022
Synergistic effect of serotonin 1A and serotonin 1B/D receptor agonists in the treatment of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats.
    Experimental neurology, 2022, Volume: 358

    Topics: Amantadine; Animals; Antiparkinson Agents; Buspirone; Dyskinesia, Drug-Induced; Levodopa; Oxazolidin

2022
Targeting 5-HT(1A) receptors in astrocytes to protect dopaminergic neurons in Parkinsonian models.
    Neurobiology of disease, 2013, Volume: 59

    Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenergic Agents; Animals; Astrocytes; Brain; Buspirone; Ce

2013
Effect of Chronic Administration of Buspirone and Fluoxetine on Inflammatory Cytokines in 6-Hydroxydopamine-lesioned Rats.
    Drug research, 2015, Volume: 65, Issue:8

    Topics: Animals; Buspirone; Cerebrospinal Fluid; Fluoxetine; Interleukin-1beta; Interleukin-6; Male; Oxidopa

2015
Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats.
    British journal of pharmacology, 2015, Volume: 172, Issue:1

    Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Buspirone; Citalopram; Dyskin

2015
Graft-induced dyskinesias fail to respond to 5HT1A agonist in the long-term.
    Movement disorders : official journal of the Movement Disorder Society, 2015, Volume: 30, Issue:6

    Topics: Brain Tissue Transplantation; Buspirone; Dyskinesias; Female; Fetal Tissue Transplantation; Humans;

2015
[The use of buspirone in clinical practice].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2015, Volume: 115, Issue:4

    Topics: Anti-Anxiety Agents; Anxiety; Buspirone; Depression; Dyskinesia, Drug-Induced; Humans; Parkinson Dis

2015
The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism.
    Psychopharmacology, 2009, Volume: 204, Issue:4

    Topics: Animals; Buspirone; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Dyski

2009
Graft-induced dyskinesias in Parkinson's disease: what is it all about?
    Cell stem cell, 2010, Aug-06, Volume: 7, Issue:2

    Topics: Animals; Brain Tissue Transplantation; Buspirone; Dyskinesias; Fetal Tissue Transplantation; Humans;

2010
Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease.
    Neurobiology of disease, 2012, Volume: 47, Issue:3

    Topics: 5,6-Dihydroxytryptamine; Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Antiparkinso

2012
Buspirone in the treatment of levodopa induced dyskinesias.
    Journal of neurology, neurosurgery, and psychiatry, 1991, Volume: 54, Issue:4

    Topics: Adult; Aged; Apomorphine; Buspirone; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Hu

1991
Buspirone in Parkinson's disease.
    Clinical neuropharmacology, 1986, Volume: 9, Issue:6

    Topics: Adult; Aged; Antiparkinson Agents; Brain; Buspirone; Dopamine; Female; Humans; Male; Middle Aged; Pa

1986